Inogen (STU:6IO) Notes Receivable: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6IO Inogen Inc STU:6IO
66 GF Score
Price €5.65
GF Value €5.99
! 3 Warning Signs
View Full Analysis

What is Inogen Notes Receivable?

Inogen STU:6IO -5.04% 66 Notes Receivable is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:6IO with a GF Score™ of 66/100 and a GF Value™ of €5.99. The stock has 3 warning signs investors should review.

Inogen's Notes Receivable for the quarter that ended in Mar. 2026 was €0.0 Mil.

Inogen Notes Receivable Historical Data

* Premium members only.

The historical data trend for Inogen's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inogen Notes Receivable Chart

Inogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Inogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:6IO
66GF Score
Inogen Inc STU:6IO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inogen Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.0 Mil mean?
Inogen (STU:6IO) has a Notes Receivable of €0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Inogen and its competitors.
Is Inogen's Notes Receivable too high?
Inogen's current Notes Receivable is €0.0 Mil. Overall, Inogen has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Inogen's Notes Receivable compare to QSI and APYX?
Inogen's Notes Receivable of €0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Inogen and its competitors. Inogen's current Notes Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inogen stock overvalued right now?
Inogen (STU:6IO) has a current Notes Receivable of €0.0 Mil. The stock's GF Value™ is €5.99, compared to a current price of €5.65 — trading 5.7% below its estimated fair value. The current Notes Receivable is €0.0 Mil. Inogen's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Inogen (STU:6IO), the current Notes Receivable is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inogen (STU:6IO) Overvalued in 2026?

Based on GuruFocus' analysis, Inogen stock appears to be undervalued. The current stock price of €5.65 is trading 5.7% below its estimated GF Value™ of €5.99.

Key valuation signals for STU:6IO:

  • Notes Receivable: €0.0 Mil
  • GF Value™: €5.99 vs. price of €5.65 (5.7% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the STU:6IO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inogen Business Description

Other Exchanges INGN:USA
Address 500 Cummings Center, Suite 2800, Beverly, MA, USA, 01915
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
66GF Score

Get the complete analysis for STU:6IO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.65
Price
€5.99
GF Value